By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has completed its acquisition of contract research organization Hypoxium and formed a wholly owned subsidiary called Horizon Discovery Services.

HDS will provide oncology translational research services, such as drug profiling, novel 2D and 3D phenotypic assays, tumor microenvironment studies, and responsive-patient prediction. The services include access to Horizon's 250-plus patient relevant human isogenic cancer cell models.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.